These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. Minniti G; Salvati M; Arcella A; Buttarelli F; D'Elia A; Lanzetta G; Esposito V; Scarpino S; Maurizi Enrici R; Giangaspero F J Neurooncol; 2011 Apr; 102(2):311-6. PubMed ID: 20686820 [TBL] [Abstract][Full Text] [Related]
7. MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. Melguizo C; Prados J; González B; Ortiz R; Concha A; Alvarez PJ; Madeddu R; Perazzoli G; Oliver JA; López R; Rodríguez-Serrano F; Aránega A J Transl Med; 2012 Dec; 10():250. PubMed ID: 23245659 [TBL] [Abstract][Full Text] [Related]
8. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952 [TBL] [Abstract][Full Text] [Related]
9. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells. Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841 [TBL] [Abstract][Full Text] [Related]
10. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
12. The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents. Siller S; Lauseker M; Karschnia P; Niyazi M; Eigenbrod S; Giese A; Tonn JC Acta Neuropathol Commun; 2021 Mar; 9(1):35. PubMed ID: 33663593 [TBL] [Abstract][Full Text] [Related]
13. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. Agnihotri S; Gajadhar AS; Ternamian C; Gorlia T; Diefes KL; Mischel PS; Kelly J; McGown G; Thorncroft M; Carlson BL; Sarkaria JN; Margison GP; Aldape K; Hawkins C; Hegi M; Guha A J Clin Invest; 2012 Jan; 122(1):253-66. PubMed ID: 22156195 [TBL] [Abstract][Full Text] [Related]
14. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide. van Nifterik KA; van den Berg J; van der Meide WF; Ameziane N; Wedekind LE; Steenbergen RD; Leenstra S; Lafleur MV; Slotman BJ; Stalpers LJ; Sminia P Br J Cancer; 2010 Jun; 103(1):29-35. PubMed ID: 20517307 [TBL] [Abstract][Full Text] [Related]
15. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W; Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102 [TBL] [Abstract][Full Text] [Related]
16. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients. Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344 [TBL] [Abstract][Full Text] [Related]
17. MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Jeuken JW; Cornelissen SJ; Vriezen M; Dekkers MM; Errami A; Sijben A; Boots-Sprenger SH; Wesseling P Lab Invest; 2007 Oct; 87(10):1055-65. PubMed ID: 17700563 [TBL] [Abstract][Full Text] [Related]
18. Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation. Nguyen SA; Stechishin OD; Luchman HA; Lun XQ; Senger DL; Robbins SM; Cairncross JG; Weiss S Clin Cancer Res; 2014 Sep; 20(18):4894-903. PubMed ID: 25078279 [TBL] [Abstract][Full Text] [Related]
19. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Lalezari S; Chou AP; Tran A; Solis OE; Khanlou N; Chen W; Li S; Carrillo JA; Chowdhury R; Selfridge J; Sanchez DE; Wilson RW; Zurayk M; Lalezari J; Lou JJ; Ormiston L; Ancheta K; Hanna R; Miller P; Piccioni D; Ellingson BM; Buchanan C; Mischel PS; Nghiemphu PL; Green R; Wang HJ; Pope WB; Liau LM; Elashoff RM; Cloughesy TF; Yong WH; Lai A Neuro Oncol; 2013 Mar; 15(3):370-81. PubMed ID: 23328811 [TBL] [Abstract][Full Text] [Related]